scholarly journals State-of-the-Art of Monoclonal Antibodies for the Treatment of Gastric Cancer

2021 ◽  
Vol Volume 15 ◽  
pp. 451-462
Author(s):  
Debora Basile ◽  
Francesca Simionato ◽  
Alessandro Cappetta ◽  
Silvio Ken Garattini ◽  
Giandomenico Roviello ◽  
...  
2004 ◽  
Vol 2 (7) ◽  
pp. 40-47 ◽  
Author(s):  
A. Cervantes ◽  
V. Georgoulias ◽  
A. Falcone

2020 ◽  
Vol 45 (2) ◽  
pp. 195-201
Author(s):  
Arzu Didem Yalcin ◽  
Kevser Onbasi ◽  
Rusen Uzun ◽  
Felix Herth ◽  
Philipp Albert Schnabel

Author(s):  
Manish S. Bhandare ◽  
Vikram Chaudhari ◽  
Shailesh V. Shrikhande

BMC Genomics ◽  
2019 ◽  
Vol 20 (1) ◽  
Author(s):  
Tao Chen ◽  
Cangui Zhang ◽  
Yingqiao Liu ◽  
Yuyun Zhao ◽  
Dingyi Lin ◽  
...  

Abstract Background Recent studies have shown that long non-coding RNAs (lncRNAs) play a crucial role in the induction of cancer through epigenetic regulation, transcriptional regulation, post-transcriptional regulation and other aspects, thus participating in various biological processes such as cell proliferation, differentiation and apoptosis. As a new nova of anti-tumor therapy, immunotherapy has been shown to be effective in many tumors of which PD-1/PD-L1 monoclonal antibodies has been proofed to increase overall survival rate in advanced gastric cancer (GC). Microsatellite instability (MSI) was known as a biomarker of response to PD-1/PD-L1 monoclonal antibodies therapy. The aim of this study was to identify lncRNAs signatures able to classify MSI status and create a predictive model associated with MSI for GC patients. Methods Using the data of Stomach adenocarcinoma from The Cancer Genome Atlas (TCGA), we developed and validated a lncRNAs model for automatic MSI classification using a machine learning technology – support vector machine (SVM). The C-index was adopted to evaluate its accuracy. The prognostic values of overall survival (OS) and disease-free survival (DFS) were also assessed in this model. Results Using the SVM, a lncRNAs model was established consisting of 16 lncRNA features. In the training cohort with 94 GC patients, accuracy was confirmed with AUC 0.976 (95% CI, 0.952 to 0.999). Veracity was also confirmed in the validation cohort (40 GC patients) with AUC 0.950 (0.889 to 0.999). High predicted score was correlated with better DFS in the patients with stage I-III and lower OS with stage I-IV. Conclusion This study identify 16 LncRNAs signatures able to classify MSI status. The correlation between lncRNAs and MSI status indicates the potential roles of lncRNAs interacting in immunotherapy for GC patients. The pathway of these lncRNAs which might be a target in PD-1/PD-L1 immunotherapy are needed to be further study.


1999 ◽  
Vol 2 (3) ◽  
pp. 151-157 ◽  
Author(s):  
Masashi Fujii ◽  
Juei Sasaki ◽  
Toshifusa Nakajima

1983 ◽  
Vol 417 (1 Oncodevelopme) ◽  
pp. 158-168 ◽  
Author(s):  
Akira Yachi ◽  
Kohzoh Imai ◽  
Yasuo Moriya ◽  
Hideo Fujita ◽  
Mariko Tanda ◽  
...  

2017 ◽  
Vol 24 (2) ◽  
pp. 427-438 ◽  
Author(s):  
Mikhail S. Karbyshev ◽  
Evgeniya S. Grigoryeva ◽  
Viktor V. Volkomorov ◽  
Elisabeth Kremmer ◽  
Alexander Huber ◽  
...  

2008 ◽  
Vol 4 (3) ◽  
pp. 305-307 ◽  
Author(s):  
Shyam Mohapatra ◽  
Homero San Juan

Sign in / Sign up

Export Citation Format

Share Document